Source link : https://www.newshealth.biz/health-news/hit-and-miss-for-cdk4-6-inhibitor-in-recurrent-brain-cancer/
HOUSTON — Progression-free survival for 6 months (PFS6) in recurrent/progressive high-grade meningioma improved more than threefold versus historical outcomes in patients who received the CDK4/6 inhibitor abemaciclib (Verzenio), a preliminary study showed. The first 24 evaluable patients had a PFS6 of 54% as compared with a historical rate of 15%. After enrollment exceeded expectations, analysis […]
Author : News Health
Publish date : 2024-11-26 15:04:39
Copyright for syndicated content belongs to the linked Source.